Characterization of N-acetylcysteine and ambroxol in anti-oxidant therapy

Respiratory Medicine

Volumn 92, Issue 4, 1998, Pages 609-623

  Gillissen, A ^a,c   Nowak, D ^b  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; AMBROXOL; ANTIOXIDANT; CATALASE; CYTOKINE; GLUTATHIONE; HYDROGEN PEROXIDE; HYDROXYL RADICAL; HYPOCHLOROUS ACID; INTERLEUKIN 1; OXIDIZING AGENT; OXYGEN RADICAL; PARACETAMOL; SCAVENGER; SUPEROXIDE DISMUTASE; SURFACTANT; TUMOR NECROSIS FACTOR ALPHA;

ADULT RESPIRATORY DISTRESS SYNDROME; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; BRONCHUS HYPERREACTIVITY; CYSTIC FIBROSIS; DEACETYLATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG TISSUE LEVEL; ENCAPSULATION; GLUTATHIONE METABOLISM; HUMAN; INFLAMMATORY CELL; INTRAVENOUS DRUG ADMINISTRATION; LUNG DISEASE; LUNG FIBROSIS; ORAL DRUG ADMINISTRATION; OXIDATIVE STRESS; PRIORITY JOURNAL; REVIEW;

EID: 0031948449     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0954-6111(98)90506-6     Document Type: Review

References (158)

1. Weiss, SJ. Oxygen, ischemia and inflammation. Acta Physiol Scand 1986; 548: 9-37.
2. Schraufstätter IU, Cochrane CG. Oxidants: types, sources, and mechanisms of injury. In: Crystal RG, West JB, eds. The lung, Scientific foundations. New York: Raven Press, 1991, pp. 1803-1810.
3. Schraufstätter IU, Hyslop PA, Jackson J et al. Oxidant and protease injury of the lung. Bull Eur Physiopathol Respir 1987; 23: 297-302.
4. Halliwell B, Gutteridge JMC. Free Radicals in Biology and Medicine, 2nd edition. Oxford: Clarendon Press, 1989.
5. Halliwell B, Cross CE. Oxygen-derived species: their relation to human disease and environmental stress. Environ Health Perspect 1994; 102: 5-12.
6. Winsel K, Becher G. Effects of ambroxol on chemiluminescence of phagocytic cells and Na-arachidonate induced bronchoconstriction in guinea pigs. Eur Respir J 1992; 5: 289s.
7. Hoidal JR, Kennedy TP. Oxidative damage and respiratory disease. In: Chow CK, ed. Cellular Antioxidant Defense Mechanisms. New York: CRC Press Inc. 1988, 53-70.
8. Jenkinson SG. Free radical effects on lung metabolism. Clin Chest Med 1989; 10: 37-47.
9. Weiss SJ, Lambert MB, Test ST. Long-lived oxidants generated by human neutrophils: characterization and bioactivity. Science 1983; 222: 625-628.
10. Haber F, Weiss JJ. The catalytic decomposition of hydrogen peroxide by iron salts. Proc R Soc London 1934; 147: 332-352.
11. Fenton HJH. Oxidation of tartaric acid in the presence of iron. J Chem Soc Trans 1894; 65: 899-910.
12. Ward PA. Oxygen radicals, cytokines, adhesion molecules, and injury. Environ Health Perspect 1994; 102: 13-16.
13. Meeting report on oxy radicals and antioxidative response in cancer: 12th Sapporo cancer seminar. Cancer Res 1993; 53: 3207-3210.
14. Jackson IH. Potential molecular mechanisms of oxidant-induced carcinogenesis. Environ Health Perspect 1994; 102: 155-158.
15. Duthie SJ, Ma M, Ross MA et al. Antioxidant supplementation decreases oxidative DNA damage in human lymphocytes. Cancer Res 1996; 56: 1291-1295.
16. -) from alveolar macrophages exposed to asbestiform and nonfibrous particles. Cancer Res 1987; 47: 1681-1686.
17. Goodglick LA, Pietras LA, Kane AG. Dissociation of lipid peroxidation from asbestos toxicity. Am Rev Respir Dis 1988; 137: A402.
18. Mossman BT, Marsh JP, Shatos MA. Alteration of superoxide dismutase activity in tracheal epithelial cells by asbestos and inhibition of cytotoxicity by antioxidants. Lab Invest 1986; 54: 204-212.
19. Adler KB, Fischer BM, Wright DT, Cohn LA et al. Interactions between respiratory epithelial cells and cytokines: relationships to lung inflammation. In: Boland BM, Cullinan J, Rogers T, eds. Cells and Cytokines in Lung Inflammation, New York: New York Academy of Sciences, 1994, pp. 128-145.
20. Kelley J. Cytokines of the lung. Am Rev Respir Dis 1990; 141: 765-788.
21. Fitzpatrick FA, Murphy RC. Cytochrome P-450 metabolism of arachidonic acid: formation and biological actions of "epoxygenase"-derived eicosanoids. Pharmacol Rev 1989; 40: 229-241.
22. Thivierge M, Rola-Pleszczynski M. Involvement of both cyclooxygenase and lipoxygenase pathways in platelet-activating factor-induced interleukin-6 production by alveolar macrophages. In: Boland BM, Cullinan J, Rogers T, eds. Cells and Cytokines in Lung Inflammation. New York: New York Academy of Sciences, 1994, pp. 213-222.
23. Wong GHW, Goeddel DV. Induction of manganous superoxide dismutase by tumour necrosis factor: possible protective mechanism. Science 1988; 242: 941-943.
24. Visner GA, Dougall WC, Wilson JM et al. Regulation of manganese superoxide dismutase by lipoplysaccharide, interleukin-1, and tumor necrosis factor. J Biol Chem 1990; 265: 2856-2864.
25. Jacobs RF, Tabor DR, Burks AW et al. Elevated Interleukin-1 release by human alveolar macrophages during the adult respiratory distress syndrome. Am Rev Respir Dis 1989; 140: 1686-1692.
26. Tsan M-F, White JE, Treanor C et al. Molecular basis for tumor necrosis factor-induced increase in pulmonary superoxide dismutase activities. Am J Physiol (Lung Cell Mol Physiol) 1990; 259: L506-L512.
27. Needleman P, Turk J, Jakschik BA et al. Arachidonic acid metabolism. Ann Rev Biochem 1986; 55: 69-102.
28. Abramson SL, Malech HL, Galin JI. Neutrophils. In: Crystal RG, West JB, eds. The Lung Scientific Foundation. New York: Raven Press, 1991, pp. 553-563.
29. White JE, Tsan M-F. Induction of pulmonary Mn superoxide dismutase mRNA by interleukin 1. Am J Physiol (Lung Cell Mol Physiol) 1994; 266: L664-L671.
30. Harris CA, Derbin KS, Hunte-McDonough B et al. Manganese superoxide dismutase is induced by IFN-gamma in multiple cell types. Synergistic induction by IFN-gamma and tumor necrosis factor or IL-1. J Immunol 1991; 147: 149-154.
31. Hirose K, Longo DL, Oppenheim JJ et al. Overexpression of mitochondrial manganese superoxide dismutase promotes the survival of tumor cells exposed to interleukin-1, tumor necrosis factor, selected anticancer drugs, and ionizing radiation. FASEB J 1993; 7: 361-368.
32. Davis WB, Rennard SI, Bitterman PB et al. Pulmonary oxygen toxicity: early reversible changes in human alveolar structures induced by hyperoxia. N Engl J Med 1983; 309: 878-883.
33. Tagan M-C, Markert M, Schaller M-D et al. Oxidative metabolism of circulating granulocytes in adult respiratory distress syndrome. Am J Med 1991; 91(Suppl. 3C): 3C-72S-3C-78S.
34. 2. J Appl Physiol 1993; 75(3): 1256-1262.
35. Tsan M-F, White JE. Kinetics of pulmonary superoxide dismutase in interleukin-1-induced oxygen-tolerant rats. Am J Physiol (Lung Cell Mol Physiol) 1992; 263: L342-L347.
36. Burger RM, Kent TA, Howitz SB et al. Mossbauer study of iron bleomycin and its activation intermediates. J Biol Chem 1983; 86: 139-142.
37. Cunningham ML, Ringrose PS, Lokesh BR. Bleomycin cytotoxicity is prevented by superoxide dismutase. Cancer Lett 1983; 21: 149-153.
38. Cantin AM, Crystal RG. Oxidants, antioxidants, and the pathogenesis of emphysema. Eur J Respir Dis 1985; 66(Suppl. 139): 7-17.
39. Church T, Pryor WA. Free-radical chemistry of cigarette smoke and its toxicological implications. Environ Health Perspect 1985; 64: 111-126.
40. Huninghake GW, Crystal RG. Cigarette smoking and lung destruction: accumulation of neutrophils in the lungs of cigarette smokers. Am Rev Respir Dis 1983; 128: 833-838.
41. 1-antitrypsm for neutrophil elastase. J Clin Invest 1991; 87: 1060-1065.
42. 2. In: Rotilio G, ed. Superoxide and Superoxide in Chemistry Amsterdam: Elsevier Science, 1985, pp. 185-188.
43. Takahashi H, Abe M, Hashimoto S et al. In vivo effect of lipopolysaccharide on alveolar and peritoneal macrophages of rats: superoxide anion generation and 5-lipoxygenase metabolism of arachidonic acid. Am J Respir Cell Mol Biol 1993; 8: 291-298.
44. Schraufstätter IU, Hyslop PA, Hinshaw DB et al. Hydrogen peroxide-induced injury of cells and its prevention by inhibitors of poly(ADH-ribose) polymerase. Proc Natl Acad Sci USA 1986; 83: 4908-4912.
45. Janssen YM, Marsh JP, Driscoll KE et al. Increased expression of manganese-containing superoxide dismutase in rat lungs after inhalation of inflammatory and fibrogenic minerals. Free Radic Biol Med 1994; 16: 315-322.
46. Marks-Konczalik J, Gillissen A, Schärling B et al. Regulation of manganese superoxide dismutase gene expression in human bronchoepithelial cells after exposure to crocidolite, silica and rockwool in vitro. Eur Respir J 1995; 8: 351s.
47. Gillissen A, Jaworska M, Wickenburg D et al. Superoxide dismutase, glutathione and catalase levels in bronchoepithelial cells after exposure to crocidolite, silica and basaltwool in vitro. Eur Respir J 1995; 8: 464s.
48. Linden M, Hakansson L, Ohlsson K et al. Glutathione in bronchoalveolar lavage fluid from smokers in related to humoral markers of inflammatory cell activity. Inflammation 1989; 13(6): 651-658.
49. Heffner JE, Repine JE. Pulmonary strategies of antioxidant defense. Am Rev Respir Dis 1989; 140: 531-554.
50. Aruoma OI. Characterization of drugs as antioxidant prophylactics. Free Radic Biol Med 1996; 20: 675-705.
51. Harris ED. Regulation of antioxidant enzymes. FASEB J 1992; 6: 2675-2683.
52. Meister A. Glutathione metabolism and its elective modification. J Biol Chem 1988; 262: 17205-17208.
53. Meister A, Larsson A. Glutathione synthetase deficiency and other disorders of the gamma-glutamyl cycle. In: Schriver CR, Beyuet AL, Sly WS et al., eds. The Metabolic Basis of Inherited Disease. New York: McGraw-Hill, 1989, pp. 855-868.
54. ++ superoxide dismutase. Chest 1993; 104: 811-815.
55. Borok Z, Buhl R, Grimes GJ et al. Effect of glutathione aerosol on oxidant-antioxidant imbalance in idiopathic pulmonary fibrosis. Lancet 1991; 338: 215-216.
56. Gillissen A, Birrer P, Buhl R et al. Recombinant secretory leukoprotease inhibitor augments glutathione levels in respiratory epithelial lining fluid. J Appl Physiol 1993; 75: 825-832.
57. Jurima-Romet M, Barber RF, Demeester J et al. Distribution studies of liposome-encapsulated glutathione administered to the lung. Int J Pharm 1990; 63: 227-235.
58. Halliwell B. Reactive oxygen species in living systems: source, biochemistry, and role in human disease. Am J Med 1991; 91: 3C-14S-3C-22S.
59. Cantin AM, Béin R. Glutathione and inflammatory disorders of the lung. Lung 1991; 169: 123-138.
60. Stockley RA, Shaw J, Burnett D. Effect of ambroxol on neutrophil chemotaxis in vitro. Agents Actions 1988; 24: 292-296.
61. Heath MF, Jacobson W. The inhibition of lysosomal phospholipase A from rabbit lung by ambroxol and its consequences for pulmonary surfactant. Lung 1985; 163: 337-334.
62. Marcatili S, Guarino C, Giannattasio A et al. Alterations of the endoalveolar surfactant after surgery with extracorporeal circulation. Respiration 1990; 57: 233-238.
63. Ventresca GP, Cicchetti V, Ferrari V. Acetylcysteine. In: Braga PC, Allegra L, eds. Drugs in Bronchial Mucology. New York: Raven Press, 1989, pp. 77-102.
64. Aruoma OI, Halliwell B, Hoey BM et al. The antioxidant action of N-acetylcysteine: its reaction with hydrogen peroxide, hydroxyl radical, superoxide, and hypochlorous acid. Free Radic Biol Med 1989; 6: 593-597.
65. Gillissen A, Jaworska M, Orth M et al. Nacystelyn and N-acetylcysteine augment cellular antioxidant defense in two distinctive ways. Respir Med 1997; 91: 159-168.
66. Vanderbist F, Maes P, Nève J. In vitro comparative assessment of the antioxidant activity of nacystelyn against three reactive oxygen species. Arzneimittel-therapie 1996; 8: 783-788.
67. Phelps DT, Deneke SM, Daley DL et al. Elevation of glutathione levels in bovine pulmonary artery endothelial cells by N-acetylcysteine. Am J Respir Cell Mol Biol 1992; 7: 293-299.
68. Deneke SM, Susanto I, Vogel KA et al. Mechanisms of use of extracelluar glutathione by lung epithelial cells and pulmonary artery endothelial cells. Am J Respir Cell Mol Biol 1995; 12: 662-668.
69. Cotgreave I, Moldéus P, Schuppe I. The metabolism of N-acetylcysteine by human endothelial cells. Biochem Pharmacol 1991; 42: 13-16.
70. Deneke SM. Induction of cysteine transport in bovine pulmonary artery endothelial cells by sodium arsenite. Biochim Biophys Acta 1992; 1109: 127-131.
71. 2 toxicity by N-acetylcysteine. Eur Respir J 1989; 2: 116-126.
72. Feddersen CO, Barth P, Püchner A et al. N-acetylcysteine vermindert funktioneile und strukturelle, ARDS-typische Lungenschädigungen bei endotoxinbehandelten Ratten. Med Klin 1993; 88(4): 198-206.
73. Ceconi C, Curello S, Cargnoni A et al. The role of glutathione status in the protection against ischaemic and reperfusion damage: effects of N-acetylcysteine. Mol Cell Cardiol 1988; 20: 5-13.
74. Eklund A, Eriksson Ö, Haklansson L et al. Oral N-acetylcysteine reduces selected humoral markers of inflammatory cell activity in BAL fluid from healthy smokers: correlation to effects on cellular variables. Eur Respir J 1988; 1: 832-838.
75. Linden M, Wieslander E, Eklund A et al. Effects of oral N-acetylcysteine on cell content and macrophage function in bronchoalveolar lavage from healthy smokers. Eur Respir J 1988; 1: 645-650.
76. Hardy JG, Everard ML, Coffiner M et al. Lung deposition of a nacystelyn metered dose inhaler formulation. J Aerosol Med 1993; 6: 37-44.
77. Marriott C, Ingham S, Coffiner M et al. Determination of the mode of action of a novel mucolytic agent, nacystelyn. Eur Respir J 1993; 6: 438s.
78. Gillissen A, Schmidt EW, Rasche B et al. The biochemical behaviour of alpha 1-antitrypsin under substitution therapy at homozygote (PI-ZZ) patients. Klin Wochenschr 1998; 67: 328-335.
79. Snider GL. Emphysema: the first two centuries - and beyond. Part II. Am Rev Respir Dis 1992; 146: 1615-1622.
80. Ruffman R, Wendel A. GSH rescue by N-acetylcysteine. Klin Wochenschr 1991; 6: 279-283.
81. Issels RD, Nagele A, Eckert K-G et al. Promotion of cystine uptake and it utilization for glutathione biosynthesis induced by cysteamine and N-acetylcysteine. Biochem Pharmacol 1988; 37: 881-888.
82. Henderson AH hayes P. Acetylcysteine as a cytoprotective antioxidant inpatients with severe sepsis: potential new use for an old drug. Crit Care 1994; 28: 1086-1088.
83. De Caro L, Chizzi A, Costa R. Pharmacokinetics and bioavailability of oral acetylcysteine in healthy volunteers. Arzneim-Forsch/Drug Res 1989; 39: 382-386.
84. Borgstrom L, Kagedal B, Paulsen P. Pharmacokinetics on N-acetylcysteine in man. Eur J Clin Pharmacol 1986; 31: 217-222.
85. Rodenstein D, De Coster A, Gazzaniga A. Pharmacokinetics of oral acetylcysteine absorption, binding and metabolism in patients with respiratory disorders. Clin Pharmacokinet 1978; 3: 247-254.
86. Cotgreave I, Eklund A, Larsson A et al. No penetration of orally administered N-acetylcysteine into bronchoalveolar lavage fluid. Eur J Respir Dis 1987; 73-77.
87. Bridgeman MME, Marsden M, Selby C et al. Effect of N-acetylcysteine on the concentrations of thiols in plasma, bronchoalveolar lavage fluid, and lung tissue. Thorax 1994; 49: 670-675.
88. Jepsen S, Herlevsen P, Knudsen P et al. Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome: a prospective, randomized, placebo-controlled study. Crit Care Med 1992; 20(7): 918-923.
89. Spies CD, Reinhart K, Witt I et al. Influence of N-acetylcysteine on indirect indicators of tissue oxygenation in septic shock patients: results from a prospective, randomized, double-blind study. Crit Care Med 1994; 22: 1738-1746.
90. Meyer A, Buhl R, Magnussen H. The effect of oral N-acetylcysteine on lung glutathione levels in idiopathic pulmonary fibrosis. Eur Respir J 1994; 7: 431-436.
91. Vecchiarelli A, Dottorini M, Pietrella D et al. Macrophage activation by N-acetylcysteine in COPD patients. Chest 1994; 105: 806-811.
92. Kleinveld HA, Demacker PNM, Stalenhoef AFH. Failure of N-acetylcysteine to reduce low-density lipoprotein oxidizability in healthy subjects. Eur J Clin Pharmacol 1992; 43: 639-642.
93. Drost E, Lannan S, Bridgeman MME et al. Lack of effect of N-acetylcysteine on the release of oxygen radicals from neutrophils and alveolar macrophages. Eur Respir J 1991; 4: 723-729.
94. Meyer A, Buhl R, Kampf S et al. Intravenous N-acetylcysteine and lung glutathione of patients with pulmonary fibrosis and normals. Am J Respir Crit Care Med 1995; 152: 1055-1060.
95. Meister A. Glutathione deficiency produced by inhibition of its synthesis, and its reversal: applications in research and therapy. Pharmacol Ther 1991; 51: 155-194.
96. Pacht ER, Timerman AP, Lykens MG et al. Deficiency of alveolar fluid of patients with adult respiratory distress syndrome. Chest 1991; 100: 1397-1403.
97. Cochrane CG, Spragg R, Revak SD. Pathogenesis of the adult respiratory distress syndrome. Evidence of oxidant activity in bronchoalveolar lavage fluid. J Clin Invest 1983; 71: 754-761.
98. Bernard GR. N-acetylcysteine in experimental and clinical acute lung injury. Am J Med 1991; 91(Suppl. 3C): 3C-54S-3C-59S.
99. Suter PM, Domenighetti G, Schaller M-D et al. N-acetylcysteine enhances recovery from acute lung injury in man. Chest 1994; 105: 190-194.
100. Cantin A, Hubbard RC, Crystal RG. Glutathione deficiency in the epithelial lining fluid of the lower respiratory tract of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis 1989; 139: 370-372.
101. Strausz J, Müller-Quernheim J, Steppling H et al. Oxygen radical production by alveolar inflammatory cells in idiopathic pulmonary fibrosis. Am Rev Respir Dis 1990; 141: 124-128.
102. Clarke SW. Chronic bronchitis in the 1990s: up-to-date treatment. Respiration 1991; 58: 43-46.
103. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995; 152: S77-S120.
104. British Thoracic Society Research Committee. Oral N-acetyl cysteine and exacerbation rates in patients with chronic bronchitis and severe airways obstruction. Thorax 1985; 40: 832-835.
105. Clemens MR, Schmid B. Freie Radikale und Antioxidantien in Hämatologie und Onkologie. Atemw-Lungenkrkh 1991; 17: S26-S34.
106. Pérez-Trallero E, Garcia-Arenzana JM, Montes M et al. Lipoprotein(A) reduction by N-acetylcysteine. Lancet 1991; 337: 672-673.
107. Kharazmi A, Nielsen H, Schiotz PO. N-acetylcysteine inhibits human neutrophil and monocyte chemotaxis and oxidative metabolism. Int J Immunopharmac 1988; 10(1): 39-46.
108. Flanagan RJ, Meredith TJ. Use of N-acetylcysteine in clinical toxicology. Am J Med 1991; 3C: 131S-139S.
109. Burgunder JM, Varriale A, Lauterburg BH. Effect of N-acetyl cysteine on plasma cysteine and glutathione following paracetamol administration. Eur J Clin Pharmacol 1989; 36: 127-131.
110. Prescott LF, Donovan JW, Jarvie DR et al. The disposition and kinetics of intravenous N-acetylcysteine in patients with paracetamol overdosage. Eur J Clin Pharmacol 1989; 37: 501-506.
111. Bonanomi L, Gazzaniga A. Toxocological, pharmacokinetic and metabolic studies of acetylcysteine. Eur J Respir Dis 1980; 61: 45-51.
112. Myers C, Bonow R, Palmeri S et al. A randomized controlled trial assessing the prevention of doxorubicin cardiomyopathy by N-acetylcysteine. Seminars in Oncology 1983; 10: 53-55.
113. Levy L, Vredevoe DL. The effect of N-acetylcysteine on cyclophosphamide immunoregulation and antitumor activity. Seminars in Oncology 1983; 10: 7-16.
114. De Vries N, Zandwijk van N, Pastorino U. The EUROSCAN study: progress report. Am J Otolaryngol 1993; 14: 62-66.
115. Zandwijk van N. N-acetylcysteine for lung cancer prevention. Chest 1995; 107: 1437-1441.
116. Cerutti P, Kapanci Y. Effects of metabolite VIII of bromhexine (Na 872) on type II epithelium of the lung. An experimental and morphological study with reference to surfactant secretion. Respiration 1979; 37: 241-251.
117. Elmer G, Kapanci Y. Effect of ambroxol on pneumocyte type II cell. A morphological and biochemical study. Curr Probl Clin Biochem 1985; 13: 47-55.
118. + absorption by canine airway epithelial cells in culture. J Pharm Pharmacol 1991; 43: 841-843.
119. Petten GR, Mears GJ, Taylor PJ. The effects of NA 872 on pulmonary maturation in the fetal lamb and rabbit. Am J Obstet Gynecol 1978; 130: 35-40.
120. Anonymous. Prevention of chronic exacerbations with ambroxol (mucosolvan retard) - an open, long-term study in 5,635 patients. Respiration 1989; 55: 84-96.
121. Olivieri D, Zavattini G, Tomasini G et al. Ambroxol for the prevention of chronic bronchitis exacerbations: long-term multicenter trial. Protective effect of ambroxol against winter semester exacerbations: a double-blind study versus placebo. Respiration 1987; 51: 42-51.
122. Mellillo G, Cocco G. Ambroxol decreases bronchial hyperreactivity. Eur J Respir Dis 1986; 69: 316-320.
123. Ericsson CH, Juhasz J, Jonsson E et al. Ambroxol and simple chronic bronchitis. Respiration 1987; 51: 33-36.
124. Germouty J, Jirou-Najou JL. Clinical efficacy of ambroxol in the treatment of bronchial stasis. Respiration 1987; 51: 37-41.
125. Passali D, Zavattini G. Multicenter study on the treatment of secretory otitis media with ambroxol. Respiration 1987; 51: 52-59.
126. Nowak D, Antczak A, Krol M et al. Antioxidant properties of ambroxol. Free Radic Biol Med 1994; 16: 517-522.
127. Rozniecki J, Nowak D. Effect of ambroxol on the chloramine-T-induced decrease of serum elastase inhibitory capacity in vitro. Lung Respir 1987; 4: 14-15.
128. Rozniecki J, Nowak D. Protective effect of ambroxol on serum elastase inhibitory capacity against chloramine-T and cigarette smoke extract. Bull Eur Physiopathol Respir 1987; 12: 366s.
129. Zimmermann RG, Weber G. Inhibition of lipid peroxidation by bromhexin, ambroxol, and N-acetylcysteine. Doc. No.: U961-0608 edn., Biberach an der Riss: Dr K Thomae GmbH, 1991.
130. Ledwozyw A, Jablonka S. Tusinska R. The effect of ambroxol on peroxidative processes in dog lung mitochondria. Pol Arch Weter 1991; 31: 105-113.
131. Nowak D, Antczak A, Pietras T et al. Protective effect of ambroxol against heat- and hydrogen peroxide-induced damage to lung lipids in mice. Eur Respir J 1994; 7: 1629-1634.
132. Nowak D, Pietras T, Antczak A et al. Inhibition of endotoxin-induced lipid peroxidation by ambroxol in mice. Lung Respir 1993; 10: 14-15.
133. Nowak D, Pietras T, Antczak A et al. Effect of bacterial lipopolysaccharide on the content of lipid peroxidation products in lungs and other organs of mice. Anton Leeuwenhoek Int J Gen M 1993; 63: 77-83.
134. Bianchi M, Mantovani A, Erroi A et al. Ambroxol inhibits interleukin 1 and tumor necrosis factor production in human mononuclear cells. Agents Actions 1990; 31: 275-279.
135. Nowak D, Pierscinski G, Drzewoski J. Ambroxol inhibits doxorubicin-induced lipidperoxidation in heart of mice. Free Radic Biol Med 1995; 19: 659-663.
136. Nowak D, Antczak A, Bialasiewicz P et al. Effect of ambroxol on cytosolic calcium rise in human polymorphonuclear leukocytes after stimulation with n-formyl-methionyl-leucyl-phenylalanine and concanavalin A. Int J Immunopathol Pharmacol 1994; 7: 47-56.
137. Donnini M, Luisetti M, Diomede L. Ambroxol reduces paraquat toxicity in the rat. In: Wichert von P, Müller B, eds. Basic Research on Lung Surfactant. Progress in Respiratory Research. Basel: Karger, 1990, pp. 329-332.
138. 2. Biochem Pharmacol 1987; 36: 1063-1067.
139. Peers SH. Flower RJ. Effects of ambroxol upon macrophage and neutrophil phospholipases. 6th Int Conf of Prostaglandins, Florence, 1986 p. 245s.
140. Rozniecki J, Nowak D. Ambroxol inhibits spontaneous migration of human neutrophils. Clin Exp Allergol 1990; 20: 27s.
141. Capsoni F, Ongari AM, Minonzio F et al. Effect of ambroxol on human phagocytic cell function. Boll Ist Sieroter Milan 1985; 64: 236-239.
142. Chitano P, di Stefano A, Finotto S et al. Ambroxol inhibits airway hyperresponsiveness induced by ozone in dogs. Respiration 1989; 55: 74-78.
143. Mezzetti M, Colombo L, Marini MG et al. A pharmacokinetic study on pulmonary tropism of ambroxol on patients under thoracic surgery. Surg Intensive Care 1990; 13: 179-185.
144. Moseley PE, Shasby DM, Brady M et al. Lung parenchymal injury induced by bleomycin. Am Rev Respir Dis 1984; 130: 1082-1086.
145. Novak Z, Varga SI, Kovacs L et al. The effects of oradexone and ambroxol pretreatment on the oxidative sensitivity of the red blood cells in preterm infants. Clin Chim Acta 1989; 182: 241-246.
146. Fegiz G, Volpino P, Piat G et al. Prevention by ambroxol of bronchopulmonary complications after upper abdominal surgery: double-blind Italian multicenter clinical study. Lung 1991; 169: 69-76.
147. Romanini BM, Sandri MG, Tosi M et al. Ambroxol for prophylaxis and treatment of broncho-pulmonary complications after chest surgery. Int J Clin Res 1986; 2: 123-127.
148. Marini A, Franzetti M, Gios G et al. Ambroxol in the treatment of idiopathic respiratory distress syndrome. An interim report on a controlled double-blind multicenter study versus placebo. Respiration 1987; 51: 60-67.
149. Thomassen MJ, Antal JM, Connors M et al. Characterization of Exosurf (surfactant)-mediated suppression of stimulated human alveolar macrophage cytokine release. Am J Respir Cell Mol Biol 1994; 10: 399-404.
150. Matalon S, Holm BA, Baker RR et al. Characterization of antioxidant activities of pulmonary surfactant mixtures. Biochim Biophys Acta 1990; 1035: 121-127.
151. Ahuja A, Oh N, Chao W et al. Inhibition of the human neutrophil respiratory burst by native and synthetic surfactant. Am J Respir Cell Mol Biol 1996; 14: 496-503.
152. Guyatt GH, Townsend M, Kazim F et al. A controlled trial of ambroxol in chronic bronchitis. Chest 1987; 92: 618-621.
153. Ericsson CH, Juhasz J, Mossberg B et al. Influence of ambroxol on tracheobronchial clearance in simple chronic bronchitis. Eur J Respir Dis 1987; 70: 163-170.
154. Dirksen H, Hermansen F, Groth S et al. Mucociliary clearance in early simple chronic bronchitis. Eur J Respir Dis Suppl 1987; 153: 145-149.
155. Davis WB, Pacht ER. Extracelluar antioxidant defenses. In: Crystal RG, West JB, Barnes PJ et al., eds. The Lung, Scientific Foundations, New York: Raven Press, 1991, pp. 1821-1828.
156. Eck HP, Gmünder H, Hartmann M et al. Low concentrations of acid-soluble thiol (cysteine) in the blood plasma of HIV-1 infected patients. Biol Chem Hoppe-Seyler 1989; 370: 101-108.
157. Jackson RM, Frank L. Ozone induced tolerance of hyperoxia in rats. Am Rev Respir Dis 1984; 129: 425-429.
158. Smith LJ, Houston M, Anderson J. Increased levels of glutathione in bronchoalveolar lavage fluid from patients with asthma. Am Rev Respir Dis 1993; 147: 1461-1464.